Cullum Jodi L, Wojciechowski Agnieszka E, Pelletier Guy, Simpson J Steven A
Department of Psychosocial Resources, Tom Baker Cancer Centre, Calgary, Alberta.
Can J Psychiatry. 2004 Feb;49(2):139-44. doi: 10.1177/070674370404900209.
To demonstrate that bupropion sustained release (SR) can reduce the symptoms of fatigue experienced by cancer patients.
We studied an open-label case series of outpatients with fatigue referred for psychiatric assessment from a tertiary care cancer centre. Inclusion criteria were the presence of fatigue or depression with marked fatigue. Clinical status was assessed using the Global Clinical Improvement scale.
Fifteen subjects with various cancer sites and psychiatric diagnoses were treated with bupropion SR (modal dose 150 mg) for up to 2 years. Most (13 of 15) saw improvement. Thirteen patients had minor, expectable side effects, and 10 patients were able to continue with bupropion for an extended time. All subjects who improved showed improvement within 2 to 4 weeks.
This is the first report that shows bupropion SR can reduce fatigue in cancer patients. Controlled studies with more homogeneous samples would be necessary to establish the efficacy of this intervention. Further studies should address whether this effect of bupropion is separate from its action as an antidepressant.
证明安非他酮缓释片（SR）可减轻癌症患者的疲劳症状。
我们研究了一个开放标签的病例系列，这些门诊患者因疲劳从三级护理癌症中心转诊进行精神科评估。纳入标准为存在疲劳或伴有明显疲劳的抑郁症。使用全球临床改善量表评估临床状况。
15名患有不同癌症部位和精神科诊断的受试者接受了安非他酮缓释片（模式剂量150毫克）治疗，长达2年。大多数（15名中的13名）病情有所改善。13名患者有轻微的、可预期的副作用，10名患者能够长期持续服用安非他酮。所有病情改善的受试者在2至4周内均有改善。
这是首份表明安非他酮缓释片可减轻癌症患者疲劳的报告。需要进行样本更同质的对照研究来确定这种干预措施的疗效。进一步的研究应探讨安非他酮的这种作用是否与其作为抗抑郁药的作用不同。
